Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FGF R2 (IIIb)

FGF R2 (IIIb)

Brief Information

Name:Fibroblast growth factor receptor 2
Target Synonym:EC:2.7.10.1,EC 2.7.10,BEK,K-sam,KGFR,FGFR2,Fibroblast Growth Factor Receptor 2,Keratinocyte Growth Factor Receptor,Bacteria-Expressed Kinase,Protein Tyrosine Kinase, Receptor Like 14,BEK Fibroblast Growth Factor Receptor,Craniofacial Dysostosis 1,Jackson-Weiss Syndrome,Pfeiffer Syndrome,Crouzon Syndrome,CD332 Antigen,EC 2.7.10.1,FGFR-2,BFR-1,CD332,BBDS,CEK3,ECT1,TK14,TK25,CFD1,KSAM,JWS,Receptor, Fibroblast Growth Factor, Type 2
Number of Launched Drugs:6
Number of Drugs in Clinical Trials:19
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

FGB-M52H5-ELISA
Mouse FGFR2 (IIIb), His TagMouse FGFR2 (IIIb), His Tag (Cat. No. FGB-M52H5) ELISA bioactivity

Immobilized Mouse FGFR2 (IIIb), His Tag (Cat. No. FGB-M52H5) at 5 μg/mL (100 μL/well) can bind Biotinylated Human FGF basic, Avitag,His Tag (Cat. No. FGC-H81E3) with a linear range of 0.039-0.625 μg/mL (QC tested).

FGB-C52H6-MALS-HPLC
Cynomolgus FGFR2 (IIIb), His Tag (Cat. No. ) MALS images

The purity of Cynomolgus FGFR2 (IIIb), His Tag (Cat. No. FGB-C52H6) is more than 90% and the molecular weight of this protein is around 34-51 kDa verified by SEC-MALS.

  • Background
    Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Synonym Name

FGF R2 (IIIb),FGFR2B,FGFR2

Background

Tyrosine-protein kinase that acts as cell-surface receptor for fibroblast growth factors and plays an essential role in the regulation of cell proliferation, differentiation, migration and apoptosis, and in the regulation of embryonic development. Required for normal embryonic patterning, trophoblast function, limb bud development, lung morphogenesis, osteogenesis and skin development. Plays an essential role in the regulation of osteoblast differentiation, proliferation and apoptosis, and is required for normal skeleton development. Promotes cell proliferation in keratinocytes and immature osteoblasts, but promotes apoptosis in differentiated osteoblasts. Phosphorylates PLCG1, FRS2 and PAK4. Ligand binding leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate. Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. FGFR2 signaling is down-regulated by ubiquitination, internalization and degradation. Mutations that lead to constitutive kinase activation or impair normal FGFR2 maturation, internalization and degradation lead to aberrant signaling. Over-expressed FGFR2 promotes activation of STAT1.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Erdafitinib G-024; JNJ-493; 890E37NHMV; JNJ-42756493 Approved Astex Pharmaceuticals Inc Balversa United States Carcinoma, Transitional Cell Janssen Biotech Inc 2019-04-12 Solid tumours; Carcinoma; Esophageal Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Bile Duct Neoplasms; Hepatic Insufficiency; Lymphoma; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details
Regorafenib DAST; BAY-73-4506 Approved Bayer AG Stivarga, Resihance Mainland China Gastrointestinal Stromal Tumors Bayer Pharma Ag 2012-09-27 Leukemia, Myeloid, Acute; Sarcoma; Gastrinoma; Colorectal Neoplasms; Gastrointestinal Stromal Tumors; Bile Duct Neoplasms; Peritoneal Neoplasms; Lymphoma, Non-Hodgkin; Lung Neoplasms; Carcinoma, Adenoid Cystic; Thyroid Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Hepatocellular; Melanoma; Neoplasm Metastasis; Gastrointestinal Neoplasms; Somatostatinoma; Solid tumours; Glucagonoma; Multiple Myeloma; Pancreatic Neoplasms; Carcinoma, Ovarian Epithelial; Carcinoma, Transitional Cell; Neoplasms; Glioblastoma; Colonic Neoplasms; Hemangiosarcoma; Carcinoma, Islet Cell; Insulinoma; Carcinoid Tumor; Rectal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms Details
Nintedanib Esylate BIBF-1120 Approved C.H. Boehringer Sohn Ag & Co. Kg Ofev, Vargatef EU systemic sclerosis-associated interstitial lung disease Boehringer Ingelheim International Gmbh 2014-10-15 Genital Neoplasms, Female; Sarcoma; Prostatic Neoplasms; systemic sclerosis-associated interstitial lung disease; Breast Neoplasms; Adenocarcinoma, Clear Cell; Peritoneal Neoplasms; Colorectal Neoplasms; Astrocytoma; Hepatic Insufficiency; Oligodendroglioma; Bronchitis; Silicosis; Gliosarcoma; Appendiceal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Idiopathic Pulmonary Fibrosis; Head and Neck Neoplasms; Telangiectasia, Hereditary Hemorrhagic; Bronchiolitis Obliterans; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Rejection of lung transplantation; Carcinoma, Renal Cell; Scleroderma, Systemic; Ovarian Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Glioblastoma; Small Cell Lung Carcinoma; Pulmonary Fibrosis; Lung Diseases, Interstitial; Multiple Myeloma; Asbestosis Details
Pemigatinib INCB-054828; INCB-54828; IBI-375 Approved Incyte Corp Pemazyre, 伯坦, 达伯坦 Mainland China Biliary Tract Neoplasms Innovent Biologics(Suzhou) Co Ltd 2020-04-17 Glioblastoma; Carcinoma, Non-Small-Cell Lung; Endometrial Neoplasms; Bile Duct Neoplasms; Urologic Neoplasms; Colorectal Neoplasms; Cholangiocarcinoma; Translocation, Genetic; Urinary Bladder Neoplasms; Solid tumours; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Carcinoma, Renal Cell; Stomach Neoplasms; Carcinoma; Biliary Tract Neoplasms Details
Lenvatinib Mesylate ER-203492-00; E-7080; MK-7902 Approved Eisai Co Ltd Lenvima, Lenvima/Kisplyx, 乐卫玛, Kisplyx Japan Carcinoma, Renal Cell Merck Sharp & Dohme Corp 2015-02-13 Carcinoma, Adenoid Cystic; Thrombosis; Thyroid Cancer, Papillary; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Melanoma; Esophageal Squamous Cell Carcinoma; Endometrial Neoplasms; Lymphoma; Thyroid Neoplasms; Colorectal Neoplasms; Hepatic Insufficiency; Cholangiocarcinoma; Breast Neoplasms; Sarcoma; Neuroendocrine Tumors; Solid tumours; Urinary Bladder Neoplasms; Adenocarcinoma, Follicular; Liver Diseases; Small Cell Lung Carcinoma; Neoplasms; Kidney Diseases; Thyroid Carcinoma, Anaplastic; Adenocarcinoma of Lung; Rejection of liver transplantation; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Renal Insufficiency; Carcinoma, Renal Cell; Liver Neoplasms; Biliary Tract Neoplasms Details
Anlotinib Dihydrochloride AL-3818 Approved Advenchen Laboratories, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 福可维 Mainland China Thyroid Neoplasms Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd 2018-05-08 Thyroid Neoplasms; Nasopharyngeal Carcinoma; Lymphoma, Extranodal NK-T-Cell; Cholangiocarcinoma; Bile Duct Diseases; Bone Neoplasms; Colorectal Neoplasms; Peritoneal Neoplasms; Gastrointestinal Stromal Tumors; Urologic Neoplasms; Sarcoma, Alveolar Soft Part; Endometrial Neoplasms; Gallbladder Neoplasms; Esophageal Squamous Cell Carcinoma; Medullary thyroid cancer (MTC); Carcinoma, Squamous Cell; Fallopian Tube Neoplasms; Glioma; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Hepatocellular; Esophageal Diseases; Paraganglioma; Adenocarcinoma; Osteoma; Gastrointestinal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Leiomyosarcoma; Head and Neck Neoplasms; Biliary Tract Neoplasms; Solid tumours; Chondrosarcoma; Liver Neoplasms; Esophageal Neoplasms; Thoracic Neoplasms; Genital Diseases, Female; Stomach Neoplasms; Pheochromocytoma; Digestive System Diseases; Gastrointestinal Diseases; Ovarian Neoplasms; Carcinoma, Renal Cell; Small Cell Lung Carcinoma; Tripl Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
BPI-17509 BPI-17509 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Solid tumours Details
CPL-304110 CPL-304110; CPL-304-110 Celon Pharma Sa Details
Gunagratinib ICP-192 Phase 2 Clinical Beijing Tiancheng Pharmaceutical Technology Co Ltd Solid tumours; Biliary Tract Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Lung Neoplasms Details
R-1530 RG1530; R-1530; RG-1530 F. Hoffmann-La Roche Ltd Details
LY-2874455 LY-2874455 Eli Lilly And Company Details
Tasurgratinib E-7090 Phase 2 Clinical Eisai Co Ltd Biliary Tract Neoplasms; Cholangiocarcinoma Details
TT-00434 TT-00434 Phase 1 Clinical TransThera Sciences (Nanjing) Inc Solid tumours; Urinary Bladder Neoplasms Details
HMPL-453 HMPL-453 Phase 2 Clinical Hutchison Huangpu Medicine (Shanghai) Co Ltd Biliary Tract Neoplasms; Solid tumours; Neoplasms, Mesothelial; Cholangiocarcinoma Details
Aprutumab ixadotin BAY-1187982 Bayer AG Details
Alofanib RPT-835 Russian Pharmaceutical Technologies Llc Details
KIN-3248 KIN-3248; KIN-003 Kinnate Biopharma Inc Details
HH185 3-D185; HH-185; 3D185; 3D-185 Phase 1 Clinical Shanghai Medicilon Inc, ShangHai HaiHe Biopharma Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Solid tumours Details
Derazantinib ARQ-087.2HCl; AQ-14741087; ARQ-087; BAL-087 Phase 1 Clinical Arqule Inc Biliary Tract Neoplasms; Carcinoma, Transitional Cell; Cholangiocarcinoma; Urogenital Neoplasms Details
DS-1123 DS-1123; DS-1123a Daiichi Sankyo Co Ltd Details
ASP-5878 ASP-5878 Astellas Pharma Inc Details
Rogaratinib BAY-1163877 Phase 2 Clinical Bayer AG Carcinoma, Transitional Cell; Neoplasms; Sarcoma; Gastrointestinal Stromal Tumors; Carcinoma, Non-Small-Cell Lung Details
ODM-203 ODM-203 Orion Corp Details
Zoligratinib CH-5183284; FF-284; Debio-1347 Chugai Pharmaceutical Co Ltd Details
Aprutumab FGFR-moAb; FGFR2-TTC; BAY-1179470 Bayer AG Details
ABSK-061 ABSK061 Phase 1 Clinical Solid tumours Details
AZD-4547 ABSK-091; AZD4547; ABSK091; AZD-4547 Phase 2 Clinical Astrazeneca Plc Solid tumours; Gastrointestinal Diseases; Stomach Neoplasms; Esophageal Neoplasms; Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Breast Neoplasms; Carcinoma, Squamous Cell; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung Details
RLY-4008 RLY-4008 Phase 2 Clinical Relay Therapeutics Inc Cholangiocarcinoma; Translocation, Genetic Details
SC-0011 SC-0011 Phase 1 Clinical Shijiazhuang Zhikang Hongren New Drug Development Co Ltd Solid tumours Details
Efruxifermin AKR-001; AMG-876; EFX Phase 2 Clinical Amgen Inc Non-alcoholic Fatty Liver Disease; Diabetes Mellitus Details
Bemarituzumab FPA-144 Phase 3 Clinical Five Prime Therapeutics Inc Solid tumours; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Transitional Cell; Neoplasms; Urinary Bladder Neoplasms; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Adenocarcinoma Details
Lucitanib AL-3810; CO-3810; S-80881 Phase 3 Clinical Advenchen Laboratories Nanjing Ltd Solid tumours; Ovarian Neoplasms; Stomach Neoplasms; Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Breast Neoplasms; Colorectal Neoplasms; Genital Neoplasms, Female; Thymus Neoplasms; Carcinoma, Small Cell; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message